Abstract
The present review describes our approach to the development of a structurally unique class of 5- HT2A ligands. On the basis of an abbreviated graphics model of a 5-HT2A serotonin receptor, it was hypothesized that introduction of an additional aromatic ring might enhance the affinity of phenylethylamine (an agent that lacks significant affinity for the 5-HT2A receptors). Continued work with such structures, and the continual refinement of graphics receptor models, ultimately led to the identification of AMDA (27, 5-HT2A Ki = 20 nM). AMDA is a 5-HT2A antagonist that, unlike certain other tricyclic 5-HT2A antagonists, binds with very low affinity at dopamine D2 receptors, the serotonin transporter, and the norepinephrine transporter. Comparative structure-affinity studies indicate that AMDA binds in a manner distinct from the tricyclic antagonists Graphics models were employed to identify possible modes of binding. This investigation illustrates the impact of a combination of classical medicinal chemistry, receptor modeling, and molecular biology on novel drug design.
Keywords: Receptor Mutagenesis, Pharmacophore Models, Tricyclic Ring System, AMDA Analogs, aminomethyl rotation
Current Topics in Medicinal Chemistry
Title: Application of Ligand SAR, Receptor Modeling and Receptor Mutagenesis to the Discovery and Development of a New class of 5-HT2A Ligands
Volume: 2 Issue: 6
Author(s): Richard B. Westkaemper and Richard A. Glennon
Affiliation:
Keywords: Receptor Mutagenesis, Pharmacophore Models, Tricyclic Ring System, AMDA Analogs, aminomethyl rotation
Abstract: The present review describes our approach to the development of a structurally unique class of 5- HT2A ligands. On the basis of an abbreviated graphics model of a 5-HT2A serotonin receptor, it was hypothesized that introduction of an additional aromatic ring might enhance the affinity of phenylethylamine (an agent that lacks significant affinity for the 5-HT2A receptors). Continued work with such structures, and the continual refinement of graphics receptor models, ultimately led to the identification of AMDA (27, 5-HT2A Ki = 20 nM). AMDA is a 5-HT2A antagonist that, unlike certain other tricyclic 5-HT2A antagonists, binds with very low affinity at dopamine D2 receptors, the serotonin transporter, and the norepinephrine transporter. Comparative structure-affinity studies indicate that AMDA binds in a manner distinct from the tricyclic antagonists Graphics models were employed to identify possible modes of binding. This investigation illustrates the impact of a combination of classical medicinal chemistry, receptor modeling, and molecular biology on novel drug design.
Export Options
About this article
Cite this article as:
Westkaemper B. Richard and Glennon A. Richard, Application of Ligand SAR, Receptor Modeling and Receptor Mutagenesis to the Discovery and Development of a New class of 5-HT2A Ligands, Current Topics in Medicinal Chemistry 2002; 2 (6) . https://dx.doi.org/10.2174/1568026023393741
DOI https://dx.doi.org/10.2174/1568026023393741 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Child and Adolescent Refugee Mental Health in Brazil: Literature Review and a Family Case Report
Adolescent Psychiatry Peripheral Immune Signatures in Alzheimer Disease
Current Alzheimer Research The Structure-AChE Inhibitory Activity Relationships Study in a Series of Pyridazine Analogues
Medicinal Chemistry Melatonin and Respiratory Diseases: A Review
Current Topics in Medicinal Chemistry N-acetylcysteine Versus Placebo for Treating Nail Biting, a Double Blind Randomized Placebo Controlled Clinical Trial
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Innovative Strategy in Treating Angina Pectoris with Chinese Patent Medicines by Promoting Blood Circulation and Removing Blood Stasis: Experience from Combination Therapy in Chinese Medicine
Current Vascular Pharmacology Modulating Gut Microbiota: An Emerging Approach in the Prevention and Treatment of Multiple Sclerosis
Current Neuropharmacology Indazole Derivatives: Promising Anti-tumor Agents
Anti-Cancer Agents in Medicinal Chemistry Folic Acid, Neurodegenerative and Neuropsychiatric Disease
Current Molecular Medicine Increased Aβ1-42 Production Sensitizes Neuroblastoma Cells for ER Stress Toxicity
Current Alzheimer Research Neurochemistry and Pharmacological Treatments: Where is the Field of Anorexia Nervosa Heading?
Central Nervous System Agents in Medicinal Chemistry The Discovery and Potential of N-Sulfonylated Dipeptide VLA-4 Antagonists
Current Topics in Medicinal Chemistry New Insight into Urate-Related Mechanism of Cardiovascular Damage
Current Pharmaceutical Design Towards a “Metabolic” Subtype of Major Depressive Disorder: Shared Pathophysiological Mechanisms May Contribute to Cognitive Dysfunction
CNS & Neurological Disorders - Drug Targets Fluorinated Diaryl Sulfides
Current Topics in Medicinal Chemistry 5-HT<sub>3</sub> Receptor Antagonism: A Potential Therapeutic Approach for the Treatment of Depression and other Disorders
Current Neuropharmacology Prospects of Developing Medicinal Therapeutic Strategies and Pharmaceutical Design for Effective Gluten Intolerance Treatment
Current Pharmaceutical Design UDP-Glucuronosyltransferases
Current Drug Metabolism A Review of the Synthesis of Quaternary Acetylcholinesterase Reactivators
Current Organic Chemistry Preventive and Protective Roles of Dietary Nrf2 Activators Against Central Nervous System Diseases
CNS & Neurological Disorders - Drug Targets